Top

Published in:

01-10-2013 | Nutrition (BV Howard, Section Editor)

Iron Deficiency and Cardiovascular Disease: An Updated Review of the Evidence

Authors: Emanuela Lapice, Maria Masulli, Olga Vaccaro

Published in: Current Atherosclerosis Reports | Issue 10/2013

Abstract

Body iron status has been suggested to be related to the development of cardiovascular disease (CVD). Biologically plausible mechanisms for this association have been described, however epidemiological studies on iron status and CVD risk have provided conflicting results. The lack of consistency is likely explained by differences in the study design, the measures used for the assessment of iron status, the definition of outcomes, and adjustment for confounders. To help clarify the available evidence, we report a systematic review of published cross-sectional, longitudinal, and intervention studies evaluating the relationship between different measures of iron status and CVD risk. The most likely scenario that emerges from the available studies is that, in the reference range, iron status has a neutral effect. Extreme conditions of iron deficiency, as well as of iron overload, are associated with modestly increased CVD risk, although with different proposed mechanisms.

•• Vashchenko G, Macgillivray RT. Multi-copper oxidases and human iron metabolism. Nutrients. 2013;5(7):2289–313. This is a recent review of human iron metabolism.PubMedCrossRef

•• Polin V, Coriat R, Perkins G, et al. Iron deficiency: from diagnosis to treatment. Dig Liver Dis. 2013. doi:10.1016/j.dld.2013.02.019. This is a systematic review of recent advances in physiology of iron metabolism and pathology of iron deficiency.PubMed

•• Muñoz-Bravo C, Gutiérrez-Bedmar M, Gómez-Aracena J, García-Rodríguez A, Navajas JF. Iron: protector or risk factor for cardiovascular disease? Still controversial. Nutrients. 2013;5(7):2384–404. This is the most recent review of the studies exploring the relation between iron overload and cardiovascular risk.PubMedCrossRef

Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–33.PubMedCrossRef

Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052–7.PubMed

Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1(8233):1293–4.PubMedCrossRef

Salonen JT, Nyyssönen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803–11.PubMedCrossRef

McCord JM. Is iron sufficiency a risk factor in ischemic heart disease? Circulation. 1991;83(3):1112–4.PubMedCrossRef

Tuomainen TP, Diczfalusy U, Kaikkonen J, Nyyssönen K, Salonen JT. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med. 2003;35(8):922–8.PubMedCrossRef

10.

Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Ann Hematol. 2008;87(3):167–73.PubMedCrossRef

11.

Gunawardena S, Dunlap ME. Anemia and iron deficiency in heart failure. Curr Heart Fail Rep. 2012;9(4):319–27.PubMedCrossRef

12.

Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol. 1997;7(1):62–8.PubMedCrossRef

13.

Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation. 1999;99(7):852–4.PubMedCrossRef

14.

• Hsu HS, Li CI, Liu CS, et al. Iron deficiency is associated with increased risk for cardiovascular disease and all-cause mortality in the elderly living in long-term care facilities. Nutrition. 2013;29(5):737–43. This study with a prospective design suggests that iron deficiency is independently associated with CVD and all-cause mortality in a particular subgroup of people such as the elderly living in long-term care facilities.PubMedCrossRef

15.

Mørkedal B, Laugsand LE, Romundstad PR, Vatten LJ. Mortality from ischaemic heart disease: sex-specific effects of transferrin saturation, serum iron, and total iron binding capacity. The HUNT study. Eur J Cardiovasc Prev Rehabil. 2011;18(5):687–94.PubMedCrossRef

16.

Ekblom K, Marklund SL, Jansson JH, et al. Iron stores and HFE genotypes are not related to increased risk of first-time myocardial infarction: a prospective nested case-referent study. Int J Cardiol. 2011;150(2):169–72.PubMedCrossRef

17.

Nordestgaard BG, Adourian AS, Freiberg JJ, et al. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem. 2010;56(4):559–67.PubMedCrossRef

18.

Corti MC, Guralnik JM, Salive ME, et al. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol. 1997;79(2):120–7.PubMedCrossRef

19.

Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative findings from the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;139(7):704–12.PubMed

20.

Marniemi J, Alanen E, Impivaara O, et al. Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis. 2005;15(3):188–97.PubMedCrossRef

21.

Kervinen H, Tenkanen L, Palosuo T, et al. Serum iron, infection and inflammation; effects on coronary risk. Scand Cardiovasc J. 2004;38(6):345–8.PubMedCrossRef

22.

Armaganijan D, Batlouni M. Serum ferritin levels and other indicators of organic iron as risk factors or markers in coronary artery disease. Rev Port Cardiol. 2003;22(2):185–95.PubMed

23.

Regnström J, Tornvall P, Kallner A, Nilsson J, Hamsten A. Stored iron levels and myocardial infarction at young age. Atherosclerosis. 1994;106(1):123–5.PubMedCrossRef

24.

van der A DL, Marx JJ, Grobbee DE, et al. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation. 2006;113(16)):1942–9.

25.

van der A DL, Grobbee DE, Roest M, et al. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2005;36(8):1637–41.CrossRef

26.

Reunanen A, Takkunen H, Knekt P, Seppänen R, Aromaa A. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med. 1995;238(3):223–30.PubMedCrossRef

27.

Magnusson MK, Sigfusson N, Sigvaldason H, et al. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 1994;89(1):102–8.PubMedCrossRef

28.

Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology. 1994;5(2):243–6.PubMedCrossRef

29.

Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69(6):1231–6.PubMed

30.

Ahluwalia N, Genoux A, Ferrieres J, et al. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr. 2010;140(4):812–6.PubMedCrossRef

31.

Salive ME, Cornoni-Huntley J, Guralnik JM, et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc. 1992;40(5):489–96.PubMed

32.

Holay MP, Choudhary AA, Suryawanshi SD. Serum ferritin-a novel risk factor in acute myocardial infarction. Indian Heart J. 2012;64(2):173–7.PubMedCrossRef

33.

• Zhou Y, Liu T, Tian C, Kang P, Jia C. Association of serum ferritin with coronary artery disease. Clin Biochem. 2012;45(16-17):1336–41. This is a systematic review and meta-analysis showing that there is an association between serum ferritin levels and increased CAD risk.PubMedCrossRef

34.

Shi Y, Zhou L, Huang LH, et al. Plasma ferritin levels, genetic variations in HFE gene, and coronary heart disease in Chinese: a case-control study. Atherosclerosis. 2011;218(2):386–90.PubMedCrossRef

35.

Yunker LM, Parboosingh JS, Conradson HE, et al. The effect of iron status on vascular health. Vasc Med. 2006;11(2):85–91.PubMedCrossRef

36.

Wolff B, Völzke H, Lüdemann J, et al. Association between high serum ferritin levels and carotid atherosclerosis in the Study of Health in Pomerania (SHIP). Stroke. 2004;35(2):453–7.PubMedCrossRef

37.

Bozzini C, Girelli D, Tinazzi E, et al. Biochemical and genetic markers of iron status and the risk of coronary artery disease: an angiography-based study. Clin Chem. 2002;48(4):622–8.PubMed

38.

Haidari M, Javadi E, Sanati A, Hajilooi M, Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem. 2001;47(9):1666–72.PubMed

39.

Manfroi WC, Zago AJ, Caramori PR, et al. Does serum ferritin correlate with coronary angiography findings? Int J Cardiol. 1999;69(2):149–53.PubMedCrossRef

40.

Mänttäri M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J. 1994;15(12):1599–603.PubMed

41.

Kiechl S, Aichner F, Gerstenbrand F, et al. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arterioscler Thromb. 1994;14(10):1625–30.PubMedCrossRef

42.

Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009;9:34.PubMedCrossRef

43.

Ekblom K, Hultdin J, Stegmayr B, et al. Iron stores and HFE genotypes are not related to increased risk of ischemic stroke. A prospective nested case-referent study. Cerebrovasc Dis. 2007;24(5):405–11.PubMedCrossRef

44.

Braun S, Ndrepepa G, von Beckerath N, et al. Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. Atherosclerosis. 2004;174(1):105–10.PubMedCrossRef

45.

Auer J, Rammer M, Berent R, et al. Body iron stores and coronary atherosclerosis assessed by coronary angiography. Nutr Metab Cardiovasc Dis. 2002;12(5):285–90.PubMed

46.

Rauramaa R, Väisänen S, Mercuri M, et al. Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. Eur Heart J. 1994;15(8):1020–7.PubMed

47.

Kim KS, Son HG, Hong NS, Lee DH. Associations of serum ferritin and transferrin % saturation with all-cause, cancer, and cardiovascular disease mortality: Third National Health and Nutrition Examination Survey follow-up study. J Prev Med Public Health. 2012;45(3):196–203.PubMedCrossRef

48.

Friedrich N, Milman N, Völzke H, Linneberg A, Jørgensen T. Is serum ferritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. Br J Nutr. 2009;102(4):594–600.PubMedCrossRef

49.

Galan P, Noisette N, Estaquio C, et al. Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et Minéraux AntioXydants) cohort. Public Health Nutr. 2006;9(1):70–4.PubMedCrossRef

50.

Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol. 2003;158(2):144–9.PubMedCrossRef

51.

Sempos CT, Looker AC, Gillum RE, et al. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol. 2000;10(7):441–8.PubMedCrossRef

52.

Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96(10):3300–7.PubMedCrossRef

53.

•• Menke A, Muntner P, Fernández-Real JM, Guallar E. The association of biomarkers of iron status with mortality in US adults. Nutr Metab Cardiovasc Dis. 2012;22(9):734–40. This study was conducted in a large cohort representative of US adults, and demonstrated with a prospective design and a long follow-up that ferritin and transferrin saturation were not associated with risk of mortality.PubMedCrossRef

54.

Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail. 2011;4(5):599–606.PubMedCrossRef

55.

Sun Q, Ma J, Rifai N, et al. Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr. 2008;138(12):2436–41.PubMedCrossRef

56.

Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation. 1994;89(6):2915–8.PubMedCrossRef

57.

Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;330(16):1119–24.PubMedCrossRef

58.

van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol. 1995;24(4):665–70.PubMedCrossRef

59.

• Kang P, Liu T, Tian C, Zhou Y, Jia C. Association of total iron binding capacity with coronary artery disease. Clin Chim Acta. 2012;413(19-20):1424–9. This study includes a case–control study, a systematic review, and a meta-analysis showing that there is an association between total iron binding capacity and decreased CAD risk.PubMedCrossRef

60.

Gillum RF, Sempos CT, Makuc DM, et al. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Followup Study. National Health and Nutrition Examination Survey. Am J Epidemiol. 1996;144(1):59–68.PubMedCrossRef

61.

Wells BJ, Mainous 3rd AG, King DE, et al. The combined effect of transferrin saturation and low density lipoprotein on mortality. Fam Med. 2004;36(5):324–9.PubMed

62.

Rajapurkar MM, Shah SV, Lele SS, et al. Association of catalytic iron with cardiovascular disease. Am J Cardiol. 2012;109(3):438–42.PubMedCrossRef

63.

•• Steen DL, Cannon CP, Lele SS, et al. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol. 2013;36(3):139–45. This study demonstrated in a large, well-characterized population that catalytic iron, a nonroutine marker of free iron, was associated with all-cause mortality independently of traditional risk factors.PubMedCrossRef

64.

Syrovatka P, Kraml P, Hulikova K, et al. Iron stores are associated with asymptomatic atherosclerosis in healthy men of primary prevention. Eur J Clin Invest. 2011;41(8):846–53.PubMedCrossRef

65.

Tuomainen TP, Punnonen K, Nyyssönen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998;97(15):1461–6.PubMedCrossRef

66.

Ndrepepa G, Braun S, Dibra A, et al. Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. Nutr Metab Cardiovasc Dis. 2005;15(6):418–25.PubMedCrossRef

67.

•• Kaluza J, Wolk A, Larsson SC. Heme iron intake and risk of stroke: a prospective study of men. Stroke. 2013;44(2):334–9. This study was conducted in a large cohort of Swedish men and demonstrated with a prospective design and a long follow-up that high heme iron intake may increase the risk of stroke.PubMedCrossRef

68.

•• Zhang W, Iso H, Ohira T, et al. Associations of dietary iron intake with mortality from cardiovascular disease: the JACC study. J Epidemiol. 2012;22(6):484–93. This study was conducted in a large cohort of Japanese subjects and demonstrated with a prospective design and a long follow-up that dietary total iron intake may increase the risk of stroke and total CVD.PubMedCrossRef

69.

de Oliveira Otto MC, Alonso A, Lee DH, et al. Dietary intakes of zinc and heme iron from red meat, but not from other sources, are associated with greater risk of metabolic syndrome and cardiovascular disease. J Nutr. 2012;142(3):526–33.PubMedCrossRef

70.

Qi L, van Dam RM, Rexrode K, Hu FB. Heme iron from diet as a risk factor for coronary heart disease in women with type 2 diabetes. Diabetes Care. 2007;30(1):101–6.PubMedCrossRef

71.

Lee DH, Folsom AR, Jacobs Jr DR. Iron, zinc, and alcohol consumption and mortality from cardiovascular diseases: the Iowa Women's Health Study. Am J Clin Nutr. 2005;81(4):787–91.PubMed

72.

van der A DL, Peeters PH, Grobbee DE, Marx JJ, van der Schouw YT. Dietary haem iron and coronary heart disease in women. Eur Heart J. 2005;26(3):257–62.

73.

Tzonou A, Lagiou P, Trichopoulou A, Tsoutsos V, Trichopoulos D. Dietary iron and coronary heart disease risk: a study from Greece. Am J Epidemiol. 1998;147(2):161–6.PubMedCrossRef

74.

Klipstein-Grobusch K, Grobbee DE, den Breeijen JH, Boeing H, Hofman A, Witteman JC. Dietary iron and risk of myocardial infarction in the Rotterdam Study. Am J Epidemiol. 1999;149(5):421–8.PubMedCrossRef

75.

Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation. 1994;89(3):969–74.PubMedCrossRef

76.

Casiglia E, Tikhonoff V, Bascelli A, et al. Dietary iron intake and cardiovascular outcome in Italian women: 10-year follow-up. J Womens Health. 2011;20(10):1565–71.CrossRef

77.

Tavani A, Gallus S, Bosetti C, et al. Dietary iron intake and risk of non-fatal acute myocardial infarction. Public Health Nutr. 2006;9(4):480–4.PubMedCrossRef

78.

Weng LC, Yeh WT, Bai CH, et al. Is ischemic stroke risk related to folate status or other nutrients correlated with folate intake? Stroke. 2008;39(12):3152–8.PubMedCrossRef

79.

Gartside PS, Glueck CJ. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr. 1995;14(1):71–9.PubMedCrossRef

80.

Liang W, Lee AH, Binns CW. Dietary intake of minerals and the risk of ischemic stroke in Guangdong province, China, 2007-2008. Prev Chronic Dis. 2011;8(2):A38.PubMed

81.

Malaviarachchi D, Veugelers PJ, Yip AM, MacLean DR. Dietary iron as a risk factor for myocardial infarction. Public health considerations for Nova Scotia. Can J Public Health. 2002;93(4):267–70.PubMed

82.

Marniemi J, Järvisalo J, Toikka T, et al. Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population. Int J Epidemiol. 1998;27(5):799–807.PubMedCrossRef

83.

Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42(9):1135–9.PubMedCrossRef

84.

Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssönen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998;148(5):445–51.PubMedCrossRef

85.

Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297(6):603–10.PubMedCrossRef

86.

Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J. 2011;162(5):949–57.e1.PubMedCrossRef

87.

Depalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. Reduction of iron stores and clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and non-smokers. Vascular. 2013;21. doi:10.1177/1708538113478776.

88.

Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail. 2012;14(4):423–9.PubMedCrossRef

89.

Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48.PubMedCrossRef

90.

Arutyunov G, Bylova N, Ivleva A, Kobalava Z. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose on patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID). Eur J Heart Fail. 2009;8(Suppl 2009):ii71.

91.

Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103–12.PubMedCrossRef

92.

Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-probrain natriuretic peptide in anemic patients and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–65.PubMedCrossRef

93.

Kansagara D, Dyer E, Englander H, Freeman M, Kagen D. Treatment of anemia in patients with heart disease: a systematic review. Washington: Department of Veterans Affairs; 2011.

Title: Iron Deficiency and Cardiovascular Disease: An Updated Review of the Evidence
Authors: Emanuela Lapice
Maria Masulli
Olga Vaccaro
Publication date: 01-10-2013
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 10/2013
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-013-0358-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2013

Imaging Atherosclerosis and Risk of Plaque Rupture

Role of Metabolic Surgery in Less Obese or Non-Obese Subjects with Type 2 Diabetes: Influence Over Cardiovascular Events

Multiple Adipose Depots Increase Cardiovascular Risk via Local and Systemic Effects

Cadmium Exposure and Clinical Cardiovascular Disease: A Systematic Review

Diabetes Remission Following Metabolic Surgery: Is GLP-1 the Culprit?

Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage